Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 126,917 shares, a growth of 59.6% from the March 15th total of 79,512 shares. Based on an average daily volume of 152,950 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are short sold.

Jupiter Neurosciences Price Performance

JUNS traded down $0.01 during trading on Wednesday, reaching $0.39. 27,121 shares of the company’s stock were exchanged, compared to its average volume of 288,154. Jupiter Neurosciences has a 1 year low of $0.31 and a 1 year high of $3.33. The company’s fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.96. The stock has a market capitalization of $14.00 million, a P/E ratio of -1.48 and a beta of 2.80.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.02 million for the quarter. Equities analysts forecast that Jupiter Neurosciences will post -0.06 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Jupiter Neurosciences

A number of institutional investors have recently modified their holdings of JUNS. Allen Capital Group LLC purchased a new stake in shares of Jupiter Neurosciences in the fourth quarter worth about $31,000. Geode Capital Management LLC grew its stake in shares of Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Finally, Yorkville Advisors Global LP purchased a new position in shares of Jupiter Neurosciences during the 4th quarter valued at approximately $135,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.